ANZICS CTG Endorsed Study

BLING III

A phase III randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients

Study Description

A phase III randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients. This is a prospective, multicentre study with 7000 patients recruited from 100 sites worldwide, open label randomised controlled trial with blinded outcome assessment.

Management Committee

Jeffrey Lipman (Chair), Stephen Brett, Menino Cotta, Joshua Davis, Jan De Waele, Joel Dulhunty, Simon Finfer, Naomi Hammond, Serena Knowles, Shay McGuinness, John Myburgh, David Paterson, Dorrilyn Rajbhandari (Project Manager), Sandra Peake, Andrew Rhodes, Jason Roberts, Claire Roger, Charudatt Shirwadkar, Therese Starr, Colman Taylor.

Administering Institution

The George Institute for Global Health

Collaborators

University of Queensland

Sample Size

7000 patients

Funding

NHMRC – Project Grant – $3,269,942
HRC NZ– Project Grant – NZ$1,195,807
UK – NIHR Portfolio
Belgium – KCA (government funding)

Project Status as of June 2019

The study is in the recruitment phase with 73 of 95 sites now recruiting. A total of 1650 patients recruited of 7000.

Collaborations have been organized with: UK (Imperial College; Dr Stephen Brett, PI Coordinator); Belgikum (The University Hospital, Ghent, Belgium; Dr Jan De Waele, European Collaborator); France (University Hospital Nimes; Dr Claire Roger, coordinating); and Sweden.

There is funding for 3 sites in Malaysia which will be initiated soon.

Reference

CTG1516-04
NCT03212990 (ClinicalTrials.gov)

Contact

Dorrilyn Rajbhandari (email)
Jeff Lipman (email)
Joel Dulhunty (email)